Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.

Published

Journal Article

Checkpoint inhibitors such as pembrolizumab, an anti-PD-1 monoclonal antibody, are a promising new category of oncological therapeutics, associated with a higher risk of immune-related adverse events including dermatological, autoimmune and endocrine sequelae. Here, we present a case of a woman 76 years of age with stage IV lung adenocarcinoma who developed a severe and steroid-refractory lichenoid dermatitis associated with pruritus on pembrolizumab. This eruption resolved completely with a short course of oral cyclosporine. Cyclosporine is a promising and effective treatment option for checkpoint inhibitor-related severe cutaneous eruptions.

Full Text

Duke Authors

Cited Authors

  • Fixsen, E; Patel, J; Selim, MA; Kheterpal, M

Published Date

  • March 2019

Published In

Volume / Issue

  • 24 / 3

Start / End Page

  • e103 - e105

PubMed ID

  • 30617087

Pubmed Central ID

  • 30617087

Electronic International Standard Serial Number (EISSN)

  • 1549-490X

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2018-0531

Language

  • eng

Conference Location

  • United States